The top two single-site targets for miR-16 are an Activin type II receptor gene (TGFbeta signaling) and Hox-A5, both known to be dysregulated at the level of protein expression in colon cancers (Wang et al. 2001). The gene discussed is HOXA5; the disease is malignant colon neoplasm.